Biotechnology

Company Overview of 3-V Biosciences, Inc.

Company Overview

3-V Biosciences, Inc. operates as a biopharmaceutical company that discovers and develops therapeutics for the treatment of oncology and infectious diseases. The company offers a TVB-2640, a fatty acid synthase inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. It also focuses on developing antiviral therapeutic candidates for respiratory syncytial virus, cytomegalovirus, and other human pathogens. The company was incorporated in 2006 and is based in Menlo Park, California.

3-V Biosciences Appoints Rekha Hemrajani as Chief Financial Officer and SVP of Business and Financial Operations

Feb 19 15

3-V Biosciences, Inc. announced that Rekha Hemrajani has joined the company as its Chief Financial Officer, SVP of Business and Financial Operations. Prior to joining 3-V, Ms. Hemrajani spent the past fourteen years in the healthcare industry most recently as Vice President, Head of Licensing and M & A Group at Onyx Pharmaceuticals.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.